Edition:
United States

Foundation Medicine Inc (FMI.OQ)

FMI.OQ on NASDAQ Stock Exchange Global Select Market

51.20USD
21 Nov 2017
Change (% chg)

-- (--)
Prev Close
$51.20
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
51,267
52-wk High
$55.95
52-wk Low
$17.15

Summary

Name Age Since Current Position

Michael Pellini

52 2017 Chairman of the Board

Steven Kafka

47 2015 President, Chief Operating Officer

Troy Cox

53 2017 Chief Executive Officer, Director

Jason Ryan

42 2015 Chief Financial Officer, Principal Financial Officer, Principal Accounting officer

Robert Hesslein

63 2012 Senior Vice President, General Counsel

Tom Civik

48 2017 Chief Commercial Officer

Vincent Miller

55 2013 Chief Medical Officer

Alexis Borisy

45 2017 Director

Daniel Day

52 2015 Director

Michael Dougherty

59 2016 Director

Sandra Horning

68 2014 Director

Evan Jones

60 2013 Independent Director

Krishna Yeshwant

38 2011 Independent Director

Biographies

Name Description

Michael Pellini

Dr. Michael J. Pellini, M.D., serves as a Chairman of the Board of the Company effective February 6, 2017. He was Chief Executive Officer, Director of the Company. Dr. Pellini joined us from Clarient, Inc. (“Clarient”), a General Electric Healthcare Company, where he held the position of president and chief operating officer from April 2008 to April 2011 and served on its board of directors from May 2007 to April 2009. Dr. Pellini served as vice president, life sciences at Safeguard Scientifics, Inc. (NYSE: SFE), a private equity and venture capital firm specializing in expansion financings, growth capital, management buyouts, recapitalizations, industry consolidations, corporate spinouts, growth stage, and early stage financings, from March 2007 to April 2008 and, as part of this role, was detailed to Clarient beginning in July 2007. Dr. Pellini received a B.A. from Boston College, an M.B.A. from Drexel University and an M.D. from Jefferson Medical College, now the Sidney Kimmel Medical College, of Thomas Jefferson University.

Steven Kafka

Dr. Steven Kafka, Ph.D., serves as a President, Chief Operating Officer of Foundation Medicine, Inc. Dr. Kafka was previously chief operating officer and chief financial officer at Aileron Therapeutics Inc. (“Aileron”), a biopharmaceutical company based in Cambridge, Massachusetts from September 2009 to October 2012. Before Aileron, from September 2006 to September 2009, Dr. Kafka was vice president of finance at Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a drug discovery and development company. Dr. Kafka earned his B.A. from Stanford University and his Ph.D. from Harvard University.

Troy Cox

Mr. Troy Cox serves as Chief Executive Officer, Director of the Company effective February 6, 2017. Mr. Cox joins the Company from Genentech, Inc. (“Genentech”) where he has worked since February 2010, most recently as a Senior Vice President, BioOncology Sales & Marketing. Before joining Genentech, Mr. Cox was employed by UCB S.A. (“UCB BioPharma”), as the President, CNS Operations with responsibility for developing and commercializing therapeutics for diseases primarily related to the central nervous system. Prior to UCB BioPharma, Mr. Cox held senior commercial leadership roles with Sanofi-Aventis and Schering-Plough. Mr. Cox received a bachelor’s degree in business administration in finance from the University of Kentucky, as well as a master’s degree in business administration from the University of Missouri.

Jason Ryan

Mr. Jason Ryan serves as a Chief Financial Officer, Principal Financial Officer, Principal Accounting officer of the Company. He previously served as our Senior Director, Finance from May 2011 to March 2012. Prior to joining us, Mr. Ryan led the finance and strategic planning functions of Taligen Therapeutics, Inc., which was acquired by Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), from May 2009 to April 2011, Codon Devices Inc. from May 2007 to May 2009, and Genomics Collaborative, Inc., which was acquired by SeraCare Life Sciences, Inc. (NASDAQ: SRLS), from September 1998 to September 2004. He began his career at Deloitte & Touche. Mr. Ryan holds a B.S. in economics from Bates College and an M.B.A. from Babson College, and earned a C.P.A. in Massachusetts.

Robert Hesslein

Mr. Robert Hesslein serves as a Senior Vice President, General Counsel of Foundation Medicine, Inc. Mr. Hesslein was previously senior vice president and deputy general counsel at Genzyme Corporation (“Genzyme”), a biotechnology company based in Cambridge, Massachusetts, which is now a wholly-owned subsidiary of Sanofi (NYSE: SNY), from 1996 to 2012. Before Genzyme, from 1990 to 1996, Mr. Hesslein was a second vice president and counsel at The New England, a mutual life insurance company. From 1978 to 1990, Mr. Hesslein was an associate and subsequently a partner at Csaplar & Bok, a Boston law firm. Mr. Hesslein earned his B.A. from Yale University and his J.D. from The Cornell Law School.

Tom Civik

Mr. Tom Civik serves as a Chief Commercial Officer of the Company. He most recently served as a vice president and franchise leader at Genentech, responsible for the commercialization efforts for several leading oncology products. Prior to joining the oncology team at Genentech, Mr. Civik led the commercial activities for a portfolio of products focused on stroke and cardiovascular disease. Mr. Civik began his tenure at Genentech in 2000 in the managed care area, holding senior leadership roles focused on delivering access for the entire Genentech portfolio. Prior to Genentech, Mr. Civik spent eight years at Sanofi between 1992 and 2000 where he held increasingly complex roles in sales, sales management and account management. Mr. Civik received a Bachelor of Arts degree from the Saint Norbert College in 1990, and a Master of Business Administration degree from the Kellogg School of Management at Northwestern University in 2005.

Vincent Miller

Dr. Vincent Miller, M.D., serves as a Chief Medical Officer of Foundation Medicine, Inc. He joined us in October 2011 and served as our Senior Vice President, Clinical Development between then and July 2013. Dr. Miller served between July 1991 and October 2011 as an attending physician, and Dr. Miller has served since November 2011 to the present as a consulting physician, at Memorial Sloan-Kettering Cancer Center. Dr. Miller earned his B.A. from the University of Pennsylvania and his M.D. from the University of Medicine and Dentistry of New Jersey in Newark.

Alexis Borisy

Dr. Alexis Borisy is re-designated as Director of the Company effective February 6, 2017. He was Chairman of the Board, Co-Founder of Foundation Medicine, Inc. He co-founded Foundation Medicine in 2009 and served as our interim Chief Executive Officer through May 2011. Since 2010, Mr. Borisy has been a partner at Third Rock Ventures, a life sciences venture capital firm focused on the formation, development and strategy of new companies. He co-founded Blueprint Medicines Corp. (NASDAQ: BPMC) in 2011 and served as its interim chief executive officer, and currently is on its board of directors. In addition, since July 2013 Mr. Borisy has served as chairman of Warp Drive Bio, LLC, a life sciences company focusing on genomics where he served as chief executive officer from 2011 to July 2013. Mr. Borisy also serves on the board of directors of Editas Medicine and Revolution Medicines, Inc. From 2007 through 2012, Mr. Borisy served as chairman of FORMA Therapeutics, Inc., a life science company focused on targeting cancers for treatment. In 2000, Mr. Borisy founded CombinatoRx, Inc. (now Epirus Biopharmaceuticals, Inc. (NASDAQ: EPRS)), a drug development company, and served as its chief executive officer and on its board of directors from 2000 to 2009. Mr. Borisy holds an A.B. in chemistry from the University of Chicago, and an A.M. from Harvard University.

Daniel Day

Mr. Daniel O’ Day serves as a member of our Board of Directors of the company .Mr. O’Day has served as chief executive officer of Roche Pharmaceuticals since September 2012 and is a member of the Roche corporate executive committee. Mr. O’Day has nearly three decades of operating expertise at Roche having served previously in various executive leadership positions for Roche Pharmaceuticals and Diagnostics. Most recently, between January 2010 and August 2012, Mr. O’Day served as chief operating officer of Roche’s Diagnostics Division. He also serves on the board of directors of Flatiron Health, Inc. (“Flatiron”), Roche Pharma (Schweiz) AG, Shanghai Roche Pharmaceuticals Ltd., Genentech and Chugai Pharmaceutical Co., Ltd. He served on the board of directors of Genentech USA, Inc. from August 2012 to December 2013 and Roche Diagnostics GmbH from January 2010 to November 2012. Mr. O’Day received a B.S. degree in biology from Georgetown University and an M.B.A. from Columbia University. Pursuant to the Investor Rights Agreement, Mr. O’Day is a Roche Designee. We believe that Mr. O’Day is qualified to serve on our Board of Directors based on his extensive leadership experience and service as a board member on numerous domestic and international biotechnology and pharmaceutical public companies.

Michael Dougherty

Mr. Michael R. Dougherty serves as Director of the Company. He brings more than 30 years of executive and operational leadership to his role as an independent director at Foundation Medicine. Mr. Dougherty will fill an existing vacancy on the board and will initially join the board’s audit committee. Mr. Dougherty most recently served as the executive chairman of Celator Pharmaceuticals until its acquisition by Jazz Pharmaceuticals in July 2016. Previously, Mr. Dougherty was chief executive officer and a member of the board of directors of Kalidex Pharmaceuticals and Adolor Corporation. Mr. Dougherty previously served in a variety of senior positions, including chief operating officer of Genomics Collaborative, chief executive officer of Magainin Pharmaceuticals, and chief financial officer at Centocor. Mr. Dougherty is a graduate of Villanova University. He currently serves on the board of directors at Cempra, Aviragen Therapeutics and Trevena, all publicly traded life sciences organizations. Mr. Dougherty also served on the board of directors for ViroPharma, Inc. from 2004 until its acquisition by Shire in 2014.

Sandra Horning

Ms. Sandra Horning, M.D., has served as a member of our Board of Directors of the company . Dr. Horning currently serves as global head, product development and chief medical officer for Roche and Genentech. She joined Roche in late 2009 as global head of oncology product development. She is an emerita professor of medicine (oncology) at Stanford University where she served as a tenured professor, practicing oncologist and investigator for more than two decades. Dr. Horning received B.A. and M.D. degrees from the University of Iowa. She completed a post-doctoral fellowship at Stanford University. Pursuant to the Investor Rights Agreement, Dr. Horning is a Roche Designee. We believe Dr. Horning’s medical experience as an oncologist and experience in the development and commercialization of hematological and oncological pharmaceutical products qualify her to serve on our Board of Directors.

Evan Jones

Mr. Evan Jones serves as an Independent Director of Foundation Medicine, Inc. has served as a member of company's Board of Directors since 2013. Since 2007, Mr. Jones has served as managing member of jVen Capital, LLC, a life sciences investment company. He also serves as chairman and chief executive officer of OpGen, Inc., a privately held genetic analysis company. Previously, he co-founded Digene Corporation (“Digene”), a publicly traded biotechnology company focused on women’s health and molecular diagnostic testing that was sold to Qiagen N.V. (NASDAQ: QGEN) in 2007. He served as chairman of Digene’s board of directors from 1995 to 2007, as Digene’s chief executive officer from 1990 to 2006, and as Digene’s president from 1990 to 1999. Mr. Jones served as a member of the board of directors of CAS Medical Systems, Inc. (NASDAQ: CASM), a developer of patient vital signs monitoring products and technologies, from June 2008 to October 2013, and currently serves on the board of directors of Fluidigm Corporation (NASDAQ: FLDM), a technology company that develops, manufactures and markets microfluidic systems in the life science industry focused on analysis of single cells and industrial genomics, since March 2011 and Veracyte, Inc. (NASDAQ: VCYT), a molecular cytology company, since 2008. Mr. Jones received a B.A. from the University of Colorado and an M.B.A. from The Wharton School at the University of Pennsylvania.

Krishna Yeshwant

Dr. Krishna Yeshwant serves as an Independent Director of Foundation Medicine, Inc., since 2011. Dr. Yeshwant currently serves as a partner at Google Ventures, a venture-capital fund. Dr. Yeshwant has been working with Google Ventures since June 2008. Before joining Google Ventures, in 1996 he founded Stanford Students Consulting, an electronic data interchange company that was acquired by Hewlett-Packard Company (NYSE: HPQ) in 2000. In 2000, he founded Recourse Technologies, Inc., a network security company that was acquired by Symantec Corporation (NASDAQ: SYMC) in 2002. Since 2009, Dr. Yeshwant has also been employed by Partners Healthcare, a not-for-profit health care system, as an Internal Medicine physician at Brigham and Women’s Hospital. Dr. Yeshwant has a B.S. in Computer Science from Stanford University, an M.D. from Harvard Medical School and an M.B.A. from Harvard Business School.

Basic Compensation